Next Generation Drug Manufacture

Every pharmaceutical drug produced for the market is the culmination of at least a decade of sustained science and engineering research that transforms a molecule into a pharmaceutical material and, ultimately, into a medicine, for the benefit of patients, society and the wider economy.

Next generation drug manufacture will require a more integrated approach to manufacturing pharmaceuticals, aimed at reducing the time and cost to market and meeting the ever increasing regulatory requirements. The Synthesis and Solid State Pharmaceutical Centre carries out research ranging from molecules to medicines with the overarching objective to better understand mechanisms, control processes and predict outcomes for the efficient and environmentally sustainable production of safe medicines.

"Bold, Ambitious, Wide Ranging and Highly Innovative"

The research programme spans the entire pharmaceutical production chain from synthesis of the molecule, to the isolation of the material, and the formulation of the medicine.

The SSPC research programme is organised into three interconnecting strands, which actively reflect the three distinct steps in the manufacture of modern medicines.

The SSPC research programme is divided into 9 platform projects, which aim towards the progression of scientific state of the art, driven by scientific challenges of the area; 8 targeted projects, which are driven by scientific challenges of specific industrial needs; and 2 linker projects, which are the interactions between the strands that concentrate effort at interfaces where the most important developments need to take place. The Centre supportes two Spokes projects: one investigating Advanced Biopharmaceutical Technologies (Biopharma) and the other on Modelling of Multi-Phase Transport Processes to  Enable Automation  in  Manufacturing (MOMEnTUM).